Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
62.65 USD | +0.21% | +2.15% | -34.95% |
26/04 | CR Double-Crane Pharmaceutical's Profit Rises 11% in Q1 as Revenue Grows 2% | MT |
26/04 | CR Double-Crane Pharmaceutical's Unit Gets Nod to Trial New Pain Medication | MT |
Evolution of the average Target Price on Crane NXT
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Crane NXT
Stifel Nicolaus | |
Deutsche Bank Securities | |
Vertical Research | |
BofA Securities | |
UBS | |
DA Davidson | |
Morningstar |
EPS Revisions
- Stock Market
- Equities
- CR Stock
- CXT Stock
- Consensus Crane NXT